Pfizer recall two batches of migraine drug Relpax

04:20 EDT 16 Aug 2019 | Pharmafile

Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination.

In a statement on the FDA website, Pfizer said: “Individuals who consume oral products contaminated with microorganisms are at risk of bacterial dissemination from the gut to the bloodstream potentially resulting in serious, life- threatening infections.”

However the firm said the risk of infection was low for the general population. The risk may be higher for those with compromised immune systems, cystic fibrosis and chronic granulomatous disease.

read more

Original Article: Pfizer recall two batches of migraine drug Relpax


More From BioPortfolio on "Pfizer recall two batches of migraine drug Relpax"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...